Managing pregnancy in inflammatory rheumatological diseases

Area of Science:

• Rheumatology
• Obstetrics
• Immunology

Background:

• Historically, pregnancy in women with inflammatory rheumatic diseases was discouraged due to safety concerns.
• Advancements in combined care have shifted this paradigm, enabling better management of these pregnancies.

Purpose of the Study:

• To review the management and outcomes of pregnancy in women with inflammatory rheumatic diseases.
• To identify key risk factors for maternal and fetal complications.
• To outline safe pharmacologic strategies during pregnancy and lactation.

Main Methods:

• Literature review of studies on pregnancy in women with inflammatory rheumatic diseases.
• Analysis of factors influencing pregnancy outcomes.
• Summary of current therapeutic approaches.

Main Results:

• The majority of pregnancies in women with inflammatory rheumatic diseases managed with combined care have favorable outcomes.
• Disease activity at conception and antiphospholipid antibodies are significant predictors of complications.
• Maternal complications include disease flares, pre-eclampsia, and thrombosis; fetal complications include fetal loss and intrauterine growth restriction.
• Corticosteroids, hydroxychloroquine, sulphasalazine, and azathioprine are commonly used and considered safe during pregnancy and lactation.
• Vaginal delivery is feasible in most cases, with cesarean section reserved for specific complications.

Conclusions:

• Combined care significantly improves pregnancy outcomes for women with inflammatory rheumatic diseases.
• Careful monitoring for disease activity and antiphospholipid antibodies is crucial.
• Appropriate pharmacologic management and delivery planning optimize maternal and fetal health.